ArticlePloS one2008
Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T cell responses.
Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 51 citations in OpenAlex.
- Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivo.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Trial
- Trogocytosis in cancer immunity and cellular immunotherapy: mechanisms, therapeutic challenges, and translational opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Trogocytosis and Allergy.Cells · 2026Review
- Trogocytosis-mediated immune evasion in the tumor microenvironment.Experimental & molecular medicine · 2025Review
- Immunization-induced antigen archiving enhances local memory CD8+ T cell responses following an unrelated viral infection.NPJ vaccines · 2024Article
- A secreted Tapasin isoform impairs cytotoxic T lymphocyte recognition by disrupting exogenous MHC class I antigen presentation.Frontiers in immunology · 2024Article
- Intercellular Transfer of Immune Regulatory Molecules Via Trogocytosis.Results and problems in cell differentiation · 2024Review
- Vaccine-induced antigen archiving enhances local memory CD8+ T cell responses following an unrelated viral infection.Research square · 2023Article
- Trogocytosis in innate immunity to cancer is an intimate relationship with unexpected outcomes.iScience · 2022Article
- ATF3 and CH25H regulate effector trogocytosis and anti-tumor activities of endogenous and immunotherapeutic cytotoxic T lymphocytes.Cell metabolism · 2022Article
- Synergies of Extracellular Vesicles and Microchimerism in Promoting Immunotolerance During Pregnancy.Frontiers in immunology · 2022Review
- Evolution of Antibodies to Native Trimeric Envelope and Their Fc-Dependent Functions in Untreated and Treated Primary HIV Infection.Journal of virology · 2021Article
- Lymphocytes and Trogocytosis-Mediated Signaling.Cells · 2021Review
- Shaping of T Cell Functions by Trogocytosis.Cells · 2021Review
- Article
- AssessingBio-protocol · 2020Article
- Tolerogenic dendritic cells in organ transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2020Review
- Trogocytosis-Mediated Intracellular Signaling in CD4Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Extracellular vesicle-mediated MHC cross-dressing in immune homeostasis, transplantation, infectious diseases, and cancer.Seminars in immunopathology · 2018Review
- Antigen Presentation in Transplantation.Trends in immunology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transporter associated with antigen processing (TAP) and the major histocompatibility complex class I (MHC-I), two important components of the MHC-I antigen presentation pathway, are often deficient in tumor cells. The restoration of their expression has been shown to restore the antigenicity and immunogenicity of tumor cells. However, it is unclear whether TAP and MHC-I expression in tumor cells can affect the induction phase of the T cell response. To address this issue, we expressed viral antigens in tumors that are either deficient or proficient in TAP and MHC-I expression. The relative efficiency of direct immunization or immunization through cross-presentation in promoting adaptive T cell responses was compared. The results demonstrated that stimulation of animals with TAP and MHC-I proficient tumor cells generated antigen specific T cells with greater killing activities than those of TAP and MHC-I deficient tumor cells. This discrepancy was traced to differences in the ability of dendritic cells (DCs) to access and sample different antigen reservoirs in TAP and MHC-I proficient versus deficient cells and thereby stimulate adaptive immune responses through the process of cross-presentation. In addition, our data suggest that the increased activity of T cells is caused by the enhanced DC uptake and utilization of MHC-I/peptide complexes from the proficient cells as an additional source of processed antigen. Furthermore, we demonstrate that immune-escape and metastasis are promoted in the absence of this DC 'arming' mechanism. Physiologically, this novel form of DC antigen sampling resembles trogocytosis, and acts to enhance T cell priming and increase the efficacy of adaptive immune responses against tumors and infectious pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.